HomeSubmit RequestSubmit First AppealView StatusUser ManualFAQFeedback

Online RTI Status Form

Enter Registration Number

CDSCO/R/2019/50325

Name UMESHCHANDRA BARKUR

Date of filing

14/09/2019

Public Authority

CENTRAL DRUGS STANDARD CONTROL ORGANISATION

Status REQUEST DISPOSED OF Date of action 18/10/2019

Reply: - Subject Expert Committee (Analgesic & Rheumatology) in its 49th meeting held on 11.04.2019 deliberated on the complainant received regarding use of the drug Zoledronic acid and opined that the reported adverse reactions like Arthralgia, Myalgia, bone pain etc. are known side effects of the sald drug. The committee also recommended that regulatory issues in this case may be addressed by the licensing authority. Accordingly, recommendation of the committee has been informed to FDA, Goa under intimation to the complainant.

Licence for manufacture, sale and distribution of drugs is granted by State Licensing Authorities appointed by respective State Governments under the provisions of Drugs and Cosmetics Act, 1940 and Rules made thereunder. In view of above, you are requested to approach concern State Licensing Authority, Goa for requisite information.

CPIO Details:-

Jayant Kumar

Phone: 011-23216367

rti.cell@cdsco.nic.in

First Appellate Authority Details :-

A. K. Pradhan

Phone: 011-23216367


rti.cell@cdsco.nic.in

Nodal Officer Details :-

Telephone Number 011-23236973

Email Id

jayantwz@gmail.com



homicide, violation of the Drugs and Cosmetics Act, 1940 and Rules. It involves criminal acts, treachery, lies and deceit.

D. Description of information required:

- a) What action will be taken by FDA Goa against Cipla Limited for manufacturing sub-standard drug causing "Grievous Hurt" within the meaning of section 320 of the IPC resulting in death of my wife.
- b) What action will be taken by FDA Goa against Cipla for conducting trials on vulnerable patients in nexus with doctors/hospitals.
- c) What action will be taken by FDA Goa against Cipla for taking the aggrieved party and a consumer for a ride by lying that they had informed the serious ADRs to DCG(I), PVPI and FDA Goa.
- d) What action will be taken by FDA Goa against Cipla for the false, derogatory, defamatory remarks on the health condition of a hale and hearty patient by portraying her as paralytic. This after Rokfos was the cause of her death. It was like rubbing salt to injury.
- e) What action will be taken against Cipla Limited for deceiving FDA authorities that Rokfos was not the cause of death. Linking imaginary diseases with imaginary treatment for the same and deceiving FDA authorities with false chemical/medical theories is against pharmacovigilance, against medical science against students of medicine and chemistry and against humanity. This defeats science itself. This again is a serious anti-national activity.

E. Time period for information required:

Within 30 days

F. Information is required by:

By Speed Post

G. Details of fees paid:

Rs.10/- Court fee stamp

Place : Mumbai

Signature of Applicant

Date: 23rd October 2019

Cell: 98201 17923

E-mail: umeshchandrabarkur@hotmail.com

Cc: Commissioner, FDA Maharashtra.